Sam-A Pharm. Co (009300) Fair Value & Analysis
Healthcare · KR · Market cap 83.2B KRW
Fair value as of: Jun 25, 2026
Analysis
Sam-A Pharm. Co (009300) currently trades at 12,740 KRW, while our model-based Fair Value estimate is 31,159 KRW — implying the stock looks roughly 144.6% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Sam-A Pharm. Co., Ltd operates as a pharmaceutical company in South Korea. The company offers a range of pharmaceutical products in the areas of respiratory, anti-biotics, anti-virals, anti-histamines, anti-fungals, dermatology, pain/inflammation, gastrointestinal, cardiovascular, metabolism, urological, and steroids, as well as psychotropic agents; and OTC products in the areas of respiratory, ant-analgesics, gastro-intestinal, topical, oral, and anti-histamines. It also provides NOMA MEGAFFECT for stress relief, eye care, memory and blood lipid concentration enhancement, endurance enhancement, and the supply of vitamins and minerals; and NOMA-F gummy, NOMA CHEWABLE tablet, and NOMA GOLD chewable tablet for growth promotion, enhancement of nutritional deficiency, and supply of vitamins. Sam-A Pharm. Co., Ltd was founded in 1945 and is based in Seoul, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Sam-A Pharm. Co (009300) undervalued?
What is the fair value of 009300?
What is the quality score of 009300?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.